Novartis CEO Vas Narasimhan is doubling down on a growth forecast for 2026, even as the Swiss drugmaker’s fourth-quarter ...
NVS tops Q4 EPS estimates as margins expand, but revenues miss the mark amid U.S. generics hitting Entresto and Promacta, ...
FRANKFURT, Feb 4 (Reuters) - Swiss drugmaker Novartis forecast a decline in 2026 operating profit in the low single-digit ...
MSN Laboratories Pvt. Ltd. can’t reopen disputes resolved in earlier litigation over the scope, validity, and infringement of ...
Novartis’ fourth-quarter performance saw net sales decline 1% at constant currencies to $13.3 billion, a reflection of the accelerating impact of U.S. competition and revenue deduction adjustments, ...
(Reuters) -Novartis failed to convince a federal court to block generic drugmaker MSN Pharmaceuticals from launching its own version of Novartis' blockbuster heart-failure drug Entresto, according to ...
Novartis (NYSE:NVS) reported full-year 2025 results marked by high single-digit sales growth, double-digit core operating income growth, and the achievement of its 40% core margin target two years ...
After more than six years of high-stakes litigation in multiple courts and regulatory fights at the Food and Drug Administration (FDA), generic versions of Novartis Pharmaceuticals Corp.
Medicare Part D usually covers Entresto. However, the exact cost of Entresto can vary. In 2022, according to the most recent data, the annual out-of-pocket cost for Entresto for people with Medicare ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results